Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases — José Miguel Rivera‐Caravaca (2021) | RDL Network
Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases
Article 2021 en
Authors
JR
José Miguel Rivera‐Caravaca
SH
Stephanie L. Harrison
BB
Benjamin J. R. Buckley
Abstract
1 min read
In COVID-19 outpatients with cardiometabolic diseases, prior use of DOAC therapy compared to VKA therapy at the time of COVID-19 diagnosis demonstrated lower risk of arterial or venous thrombotic outcomes, without increasing the risk of bleeding.
David Seiffge, Maurizio Paciaroni, Duncan Wilson, Masatoshi Koga, Kosmas Macha, Manuel Cappellari, Sabine Schaedelin, Clare Shakeshaft, Masahito Takagi, Georgios Tsivgoulis, Bruno Bonetti, Bernd Kallmünzer, Shoji Arihiro, Andrea Alberti, Alexandros A. Polymeris, Gareth Ambler, Sohei Yoshimura, Michele Venti, Leo H. Bonati, Keith W. Muir, Hiroshi Yamagami, Sebastian Thilemann, Riccardo Altavilla, Nils Peters, Manabu Inoue, Tobias Bobinger, Giancarlo Agnelli, Martin M. Brown, Shoichiro Sato, Monica Acciarresi, Hans Rolf Jäger, Paolo Bovi, Stefan Schwab, Philippe Lyrer, Valeria Caso, Ḱazunori Toyoda, David J. Werring, Stefan T. Engelter, Gian Marco De Marchis
Discussion(0)
No comments yet. Be the first to comment.